文献速递白血病MDS 与骨髓增殖性肿瘤

剪接因子基因突变纳入急性髓系白血病现行风险分层的附加价值

Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification.
PubMed 文献 · Blood Adv · 2021-01-01

该研究在1447例急性髓系白血病及高危骨髓增生异常综合征患者中分析剪接因子(SF)突变与临床特征及预后的关系。SF突变见于22%患者,与不良临床特征及更短的无事件生存和总生存相关。研究建议将SF突变纳入预后分类系统,并重新评估RUNX1突变的不良预后价值。

要点

  • SF突变见于22%的AML/高危MDS患者,与不良临床特征及更短生存相关。
  • ELN 2017预后良好及中等风险组中,SF3B1突变提示预后较差。
  • 合并SF突变与RUNX1突变者预后尤其不良,RUNX1突变的不良价值可能仅限于与SF突变共存时。

核心结论

  • 建议将SF突变纳入AML预后分类系统:SF3B1突变在与良好风险特征共存时可视为中等预后因素,对现行ELN 2017中等风险患者则为不良预后因素。
  • 现行不良因素RUNX1突变的预后价值似乎仅限于其与SF突变共存时。

研究设计与样本

  • 回顾性分析1447例急性髓系白血病及高危骨髓增生异常综合征患者,研究SF突变与临床特征、细胞遗传学和分子异常及临床结局的关联。

主要发现

  • SF突变见于22%的患者,与年龄较大、既往髓系疾病及不良风险因素(RUNX1和ASXL1突变)相关。
  • 携带SF突变患者无事件生存和总生存显著缩短。
  • 在ELN 2017预后良好和中等风险组中,SF3B1突变提示预后相对较差。
  • 同时携带SF突变和RUNX1突变的患者预后尤其不良。
  • 无4种最常见SF突变的患者中,RUNX1突变与相对较好的结局相关,与中等风险患者可比。

关键数值与推荐

  • SF突变见于22%的AML/高危MDS患者。
  • ELN 2017良好和中等风险组中,SF3B1突变提示预后相对较差。
  • 合并SF突变与RUNX1突变者预后尤其不良。
  • 无4种最常见SF突变时,RUNX1突变结局与中等风险患者可比。

临床怎么用

  • 对AML患者进行SF基因突变检测,尤其关注SF3B1突变。
  • 在ELN 2017风险分层中,对良好风险伴SF3B1突变者考虑上调风险,对中等风险伴SF3B1突变者视为不良预后因素。
  • 评估RUNX1突变预后意义时需考虑是否合并SF突变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Splicing factor (SF) mutations are important contributors to the pathogenesis of hematological malignancies; however, their relevance in risk classification of acute myeloid leukemia (AML) warrants further investigation. To gain more insight into the characteristics of patients with AML carrying SF mutations, we studied their association with clinical features, cytogenetic and molecular abnormalities, and clinical outcome in a large cohort of 1447 patients with AML and high-risk myelodysplastic syndrome. SF mutations were identified in 22% of patients and were associated with multiple unfavorable clinical features, such as older age, antecedent myeloid disorders, and adverse risk factors (mutations in RUNX1 and ASXL1). Furthermore, they had significantly shorter event-free and overall survival. Notably, in European LeukemiaNet (ELN) 2017 favorable- and intermediate-risk groups, SF3B1 mutations were indicative of relatively poor prognosis. In addition, patients carrying concomitant SF mutations and RUNX1 mutations had a particularly adverse prognosis. In patients without any of the 4 most common SF mutations, RUNX1 mutations were associated with relatively good outcome, which was comparable to that of intermediate-risk patients. In this study, we propose that SF mutations be considered for incorporation into prognostic classification systems. First, SF3B1 mutations could be considered an intermediate prognostic factor when co-occurring with favorable risk features and as an adverse prognostic factor for patients currently categorized as having intermediate risk, according to the ELN 2017 classification. Second, the prognostic value of the current adverse factor RUNX1 mutations seems to be limited to its co-occurrence with SF mutations.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. van der Werf I, Wojtuszkiewicz A, Meggendorfer M, et al. Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification. Blood Adv. 2021. PMID: 34448812. doi:10.1182/bloodadvances.2021004556

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。